Cambium Bio Limited (ASX:CMB)

Australia · Delayed Price · Currency is AUD

0.5400

0.00 (0.00%)

At close: Oct 5, 2026

Market Cap	15.89M +36.4%
Revenue (ttm)	1.23M +58.2%
Net Income	-4.10M
EPS	-0.17
Shares Out	29.43M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	64
Open	0.5400
Previous Close	n/a
Day's Range	0.5400 - 0.5400
52-Week Range	0.3400 - 0.6000
Beta	-0.52
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 4, 2026

About Cambium Bio

Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia. [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2013

Country Australia

Stock Exchange Australian Securities Exchange

Ticker Symbol CMB

Full Company Profile

Financial Performance

In fiscal year 2026, Cambium Bio's revenue was 1.23 million, an increase of 58.17% compared to the previous year's 774,882. Losses were -4.10 million, 6.55% more than in 2025.

Financial Statements